Parkinson’s Laser Early Stimulation Experiment

PD results from loss of brain cells that produce dopamine. Available treatments for PD either add dopamine to the brain or increase the activity of the brain’s remaining dopamine. Laser therapy has been shown to heal damaged cells in areas outside the brain. The PLEASE study will see whether laser can heal the damaged cells in PD.

Parkinson Disease has three major manifestations:

  • Tremor at rest
  • Stiffness
  • Slowed movements
  • Bradykinesia


People who have PD will complain of difficulty walking, poor balance, and poor hand coordination. Stiffness often occurs in facial muscles resulting in “mask face” appearance. Dementia is uncommon, but many PD sufferers notice moderate slowing of memory. 

Problem:  Effective treatment of mild to moderate Parkinson Disease.

Hypothesis: A course of treatments with superior Class IV laser targeted to specific areas of the brain will result in significant reduction of functional and neuropsychological sequelae of PD.


Relevance: Effective treatment is essential to minimize the long-term damage and disability associated with PD.


Week of Study                  Activity

1                                        Initial testing

2-5                                    1st 18 Laser visits

6                                       2nd testing session

7-19                          Waiting period between treatments

20                                     3rd testing session

21-25                               2nd 18 Laser session

26                                     4th testing session

Laser Effects:


1. Activates Mitochrondrial respiratory chain, increasing ATP synthesis

2. Increases Neurogenesis and blood flow in the areas treated

3. Stimulates transcription factors moderating expression of >100 genes and increases expression and activation of Nerve Growth Factors

4. May contribute to brain remodeling


Who can Participate:

Adults with PD who don’t have other serious illnesses that would interfere with laser treatment.  Participant should remain on your PD medicines for the entire study.  Participants may change other medicines (high blood pressure pills for example), but participants who change PD medicines will have to leave the study. The study will take place over six months.